Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment

Transfusion

Volumn 55, Issue 7, 2015, Pages 1736-1744

  Keil, Shawn D ^a   Bengrine, Abderrahmane ^b   Bowen, Richard ^c   Marschner, Susanne ^a   Hovenga, Nick ^a   Rouse, Lindsay ^a   Gilmour, Denise ^a   Duverlie, Gilles ^b   Goodrich, Raymond P ^a  

^a Terumo BCT   (United States)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOFLAVIN; PHOTOSENSITIZING AGENT;

ARTICLE; ENCEPHALOMYOCARDITIS VIRUS; HEPATITIS A VIRUS; HEPATITIS C VIRUS; INFLUENZA VIRUS A; LA CROSSE VIRUS; NONHUMAN; PHOTOCHEMISTRY; PLASMA; PSEUDORABIES VIRUS; SINDBIS VIRUS; THROMBOCYTE; ULTRAVIOLET RADIATION; VESICULOVIRUS; VIRUS INACTIVATION; VIRUS LOAD; DRUG EFFECTS; HUMAN; RADIATION RESPONSE; RNA VIRUS; VIROLOGY;

BLOOD PLATELETS; HUMANS; PHOTOSENSITIZING AGENTS; PLASMA; RIBOFLAVIN; RNA VIRUSES; ULTRAVIOLET RAYS; VIRAL LOAD; VIRUS INACTIVATION;

EID: 84937024344     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13030     Document Type: Article

References (38)

1. Roth WK, Busch MP, Schuller A, et al., International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2012; 102: 82-90.
2. O'Brien SF, Yi QL, Fan W, et al., Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services. Vox Sang 2012; 103: 83-6.
3. Weusten J, Vermeulen M, van Drimmelen H, et al., Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms. Transfusion 2011; 51: 203-15.
4. Centers for Disease Control and Prevention (CDC). HIV transmission through transfusion-Missouri and Colorado, 2008. MMWR Morb Mortal Wkly Rep 2010; 59: 1335-9.
5. Centers for Disease Control and Prevention (CDC). Fatal West Nile virus infection after probable transfusion-associated transmission-Colorado, 2012. MMWR Morb Mortal Wkly Rep 2013; 62: 622-4.
6. Montgomery SP, Brown JA, Kuehnert M, et al., Transfusion-associated transmission of West Nile virus, United States 2003 through 2005. Transfusion 2006; 46: 2038-46.
7. Petersen LR, Busch MP,. Transfusion-transmitted arboviruses. Vox Sang 2010; 98: 495-503.
8. Meny GM, Santos-Zabala L, Szallasi A, et al., West Nile virus infection transmitted by granulocyte transfusion. Blood 2011; 117: 5778-9.
9. US Food and Drug Administration. Guidance for industry: use of nucleic acid tests to reduce the risk of transmission of West Nile virus from donors of whole blood and blood components intended for transfusion. Rockville (MD): US Food and Drug Administration; 2009 [cited 2014 Dec 16]; Available from: http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm189464.pdf.
10. Florea AV, Ionescu DN, Melhem MF,. Parvovirus B19 infection in the immunocompromised host. Arch Pathol Lab Med 2007; 131: 799-804.
11. De Renzo A, Azzi A, Zakrzewska K, et al., Cytopenia caused by parvovirus in an adult ALL patient. Haematologica 1994; 79: 259-61.
12. Wilder-Smith A,. Dengue infections in travellers. Paediatr Int Child Health 2012; 32Suppl1: 28-32.
13. Guzman A, Isturiz RE,. Update on the global spread of dengue. Int J Antimicrob Agents 2010; 36Suppl1: S40-2.
14. Banu S, Hu W, Guo Y, et al., Dynamic spatiotemporal trends of dengue transmission in the Asia-Pacific region, 1955-2004. PLoS One 2014; 9: e89440.
15. Vazeille M, Moutailler S, Coudrier D, et al., Two Chikungunya isolates from the outbreak of La Reunion (Indian Ocean) exhibit different patterns of infection in the mosquito, Aedes albopictus. PLoS One 2007; 2: e1168 -
16. Centers for Disease Control and Prevention (CDC). Detection of West Nile Virus in blood donations-United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52: 769-72.
17. Cardo LJ, Salata J, Mendez J, et al., Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 2007; 37: 131-7.
18. Tonnetti L, Proctor MC, Reddy HL, et al., Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion 2010; 50: 1019-27.
19. Cardo LJ, Rentas FJ, Ketchum L, et al., Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 2006; 90: 85-91.
20. Keil SD, Kiser P, Sullivan JJ, et al., Inactivation of Plasmodium spp. in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfusion 2013; 53: 2278-86.
21. Goodrich RP, Gilmour D, Hovenga N, et al., A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009; 49: 1205-16.
22. Rentas F, Harman R, Gomez C, et al., Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model. Transfusion 2007; 47: 240-7.
23. Keil SD, Saakadze N, Bowen R, et al., Riboflavin and ultraviolet light for pathogen reduction of murine cytomegalovirus in blood products. Transfusion 2005; 55: 858-63.
24. ICH Q5A. Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Geneva: ICH; 1998. Appendix 2, p. 26.
25. Ruane PH, Edrich R, Gampp D, et al., Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877-85.
26. Nakabayashi H, Taketa K, Miyano K, et al., Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982; 42: 3858-63.
27. Helle F, Vieyres G, Elkrief L, et al., Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol 2010; 84: 11905-15.
28. Fournier C, Helle F, Descamps V, et al., Natural selection of adaptive mutations in non-structural genes increases trans-encapsidation of hepatitis C virus replicons lacking envelope protein genes. J Gen Virol 2013; 94: 996-1008.
29. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. CPMP/BWP/268/95. London: The European Agency for the Evaluation of Medicinal Products; 1996.
30. Goodrich RP, Custer B, Keil S, et al., Defining adequate pathogen reduction performance for transfused blood components. Transfusion 2010; 50: 1827-37.
31. Assal A, Barlet V, Deschaseaux M, et al., Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201. Transfusion 2009; 49: 289-300.
32. Keitel S,. Guide to the preparation, use and quality assurance of blood components. 17th ed. Strasbourg: Council of Europe; 2013. p. 356-61.
33. Keil SD, Miklauz MM, Gilmour DI, et al., Photochemical inactivation of human hepatitis B virus using the Mirasol pathogen reduction technology (PRT) system as measured by PCR [poster abstract]. Vox Sang 2010; 91-516.
34. Owada T, Kaneko M, Matsumoto C, et al., Establishment of culture systems for Genotypes 3 and 4 hepatitis E virus (HEV) obtained from human blood and application of HEV inactivation using a pathogen reduction technology system. Transfusion 2014; 54: 2820-7.
35. Vanlandingham DL, Keil SD, Horne KM, et al., Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Transfusion 2013; 53: 284-90.
36. Tan LK, Lam S, Low SL, et al., Evaluation of pathogen reduction systems to inactivate dengue and chikungunya viruses in apheresis platelets suspended in plasma. Adv Infect Dis 2013; 1-9.
37. Custer B, Agapova M, Martinez RH,. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010; 54: 2641-73.
38. Mundt JM, Rouse L, Van den Bossche J, et al., Chemical and biological mechanisms of pathogen reduction technologies. Photochem Photobiol 2014; 90: 957-64.